申请人:Wan Yongqin
公开号:US20080221192A1
公开(公告)日:2008-09-11
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC kinases.
本发明提供了一类新型化合物,包括该类化合物的药物组合物以及使用该类化合物治疗或预防与异常或失调激酶活性相关的疾病或障碍的方法,特别是涉及Abl、Bcr-Abl、cSrc、TPR-Met、Tie2、MET、FGFR3、Aurora、Axl、Bmx、BTK、c-kit、CHK2、Flt3、MST2、p70S6K、PDGFR、PKB、PKC、Raf、ROCK-H、Rsk1、SGK、TrkA、TrkB和TrkC激酶异常活化的疾病或障碍。